ABSTRACT

Conclusion:

The antineovascular effect of bevacizumab is found to be higher than pegaptanib in the doses that we used in our experimental corneal neovascularisation model.

Results:

There were no statistically significant differences in burn and neovascularisation scores between three groups (p= 0.173 and p= 0.082 respectively). The area of neovascularization at the cornea surface was 73.83±6.67% in the control group, 59.84±6.85% in the bevacizumab group and 82.96 ±5.59% in the pegaptanib group (p= 0.001). Histological examination show that the avarage number of corneal vessels were 13.05 ± 3.21 in the control group, 8.86 ± 2.89 in the bevacizumab group and 12.67 ± 2.04 in the pegaptanib group (p= 0.052).

Methods:

Right eyes of twenty one guinea pigs were chemically cauterized. The subjects were divided into three groups. The first group (control group) received subconjunctival injection of balanced salt solution, the second group received subconjunctival injection of 1 mg bevacizumab, the third group received subconjunctival injection of 0.15 mg pegaptanib sodium simultaneously with cauterization. After determining the burn and neovascularization scores for all groups the animals were killed on the 10th day and histologic evaluation were performed.

Purpose:

To compare the effect of subconjunctival injection of bevacizumab and pegaptanib sodium on experimental corneal neovascularization in guinea pigs.